Vienna, Austria

ESTRO 2023

Session Item

Poster (Digital)
Quality of life in oligometastatic prostate cancer patients treated with SBRT using EORTC form
Jing Ma, Germany


Quality of life in oligometastatic prostate cancer patients treated with SBRT using EORTC form

Jing Ma1, Paul Rogowski2, Christian Trapp1, Nina Schmidt-Hegemann1, Claus Belka1, Minglun Li1

1University Hospital LMU , Radiation Oncology, munchen, Germany; 2University Hospital LMU , Radiation Oncology, Munich, Germany

Show Affiliations
Purpose or Objective

To evaluate the quality of life in patients with oligometastatic prostate cancer treated with stereotactic ablative body radiotherapy (SBRT) using EORTC QLQ-C30 and -PR25 questionnaires

Material and Methods

In this prospective study, 73 consecutive patients receiving SBRT to 110 metastatic lesions (91 bones, 14 lymph nodes, 5 local recurrences) were included from Sep. 2019 to Oct. 2022.

105 lesions were treated with 5x6Gy stereotactic ablative body radiotherapy, three lesions with 10x4 Gy, 2 lesions with 5x5 Gy, respectively. Each patient was asked to fulfil EORTC QLQ-C30 and -PR25 questionnaires before RT, at RT end, 3 months 1 and 2 years after RT, respectively. Diverse functional scores (100 for the best and 0 for the worst functioning) and symptom scores (100 for the strongest and 0 for no symptoms) were calculated at each time point.


In general, QLQ-C30 functional scores before RT were satisfactory and symptom scores were sparse. QLQ-C30 symptom scores before RT were also sparse except urinary symptoms. The sexual functional scores were modest, probably due to the old age (median 74).

At RT end, there was a slight decline of role functional scores and a remarkable increase of symptom scores in terms of fatigue, loss of appetite and incontinence aid. The decline of other functional scores were moderate. The increase of other symptom scores were also moderate except insomnia and diarrhoea, which even presented a decrease.

Three months after RT, physical and sexual function almost recovered to their baseline level and sexual activity recovered only partially, while role function remained stable. Interestingly, general healthy status, cognitive, emotional and social function increase over its baseline. Most symptoms largely relieved, while fatigue, nausea/vomiting only partially relieved. Interestingly, pain, dyspnoea and financial difficulties improved over baseline. Incontinence aid, insomnia and hormonal treatment-related symptoms went worse.

One year after RT, most functional and symptom scores remained stable compared to the previous time point. However, GHS, emotional function, cognitive function, social function, diarrhoea, urinary and bowel symptoms turned better over baseline while role function, fatigue, constipation, insomnia further went worse. Two year after RT, almost all the functional and symptom scores remained stable compared to the one-year time point except insomnia, which went a little worse.


Stereotactic ablative body radiotherapy (SBRT) of oligometastatic prostate cancer caused a decline of most functions and worsening of symptoms, which mainly recovered to the baseline 3 months after RT and remained stable at 1 and 2 year at follow-up.